Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Irinotecan in Gastric Adenocarcinoma
NCT03400592Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in gastric adenocarcinoma, sponsored by Peking University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03400592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400592.